Jason Paragas is an accomplished entrepreneur and innovator in the biotechnology sector. As the CEO and founder behind DVLP Medicines, he leads the charge in developing technological solutions to re-imagine drug development being AI native. His entrepreneurial prowess was evident during his tenure as President and founder of SaponiQx, where he successfully merged AI, synthetic biology, and immunology to revolutionize vaccine development, securing substantial investments and establishing a
solid product pipeline.

His expertise extends to venture capital, where he made pivotal seed-stage investments in biotech at Social Impact Capital and continues to mentor emerging companies. Paragas’ strategic roles have included Vice President for External Innovation at Valo Health and Director of Innovation at Lawrence Livermore National Laboratory, where he championed AI-driven precision medicine initiatives. This initiative positioned the lab to use AI to engineer the first antibodies to COVID days after the first RNA sequences was published.

A key figure in the Cancer Moonshot project, Paragas excelled in fostering collaborations that leveraged computational models and machine learning to advance medical research. He formed a public private partnership called ATOM. ATOM is a consortium between UCSF, LLNL, NCI, NVIDIA and GSK which produced one of the first generative AI drug discovery platforms. His advisory roles with the Department of Energy and contributions during the Ebola crisis underscore his impact beyond healthcare.

Paragas’ diverse experience encompasses leading a strategic scientific strategy shift for Department of Defense biodefense investments and co-inventing an Ebola vaccine at NIAID. His advisory contributions to government panels and multiple Secretary of Energy appreciation awards attest to his dedication to innovation and mission focused outcomes.